Secondary amenorrhoea is frequently caused by hypothalamic hypogonadism in highly athletic women. This condition can be attributed to stress or excessive physical activity. Premature ovarian failure would be indicated by elevated FSH levels in the blood.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

The causes of amenorrhoea vary depending on the type. Primary amenorrhoea may be caused by gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, and thyrotoxicosis. Meanwhile, secondary amenorrhoea may be caused by stress, excessive exercise, PCOS, Sheehan’s syndrome, Asherman’s syndrome, and other underlying medical conditions.

To diagnose amenorrhoea, initial investigations may include pregnancy tests, full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels. Management of amenorrhoea involves treating the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause and treat the underlying cause accordingly. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis and other complications.

In conclusion, amenorrhoea is a condition that requires proper diagnosis and management. Understanding the causes and appropriate investigations can help in providing the necessary treatment and care for women experiencing this condition.

Copper IUD as Emergency Contraception in the UK

A copper-containing intrauterine device (IUD) can be used as emergency contraception in the UK. It can be inserted within 120 hours (five days) of the first episode of unprotected sexual intercourse or up to five days after the earliest expected date of ovulation, regardless of the number of episodes or time since unprotected sex. A negative pregnancy test is not required before insertion of the copper IUD as emergency contraception.

It is important to note that the copper IUD should not be used from 48 hours to four weeks postpartum, as it falls under the UK medical eligibility criteria category 3. This means that it is advised not to be used during this time. Additionally, there is no need for the patient to have taken the progesterone emergency contraception pill beforehand as they will be using the copper device as their emergency contraception. Overall, the copper IUD is a safe and effective option for emergency contraception in the UK.

Management of Asymptomatic Fibroids in Women

The absence of menorrhagia is an important point to note in the management of asymptomatic fibroids in women. According to guidelines, annual follow-up to monitor size and growth is recommended for such cases. However, routine referral to a gynaecologist is not required unless there are symptoms that have not improved despite initial treatments, complications, fertility or obstetric problems associated with fibroids, or a suspicion of malignancy. Treatment options for menorrhagia associated with fibroids are available but have no role in the management of small asymptomatic fibroids. NSAIDs and/or tranexamic acid should be stopped if symptoms have not improved within three menstrual cycles. It is important to consider these factors when managing asymptomatic fibroids in women.

Contraceptive Methods and Their Associated Risks of Unintended Pregnancy

When it comes to preventing unintended pregnancy, not all contraceptive methods are created equal. The risk of unintended pregnancy in the first year of typical use of the combined oral contraceptive pill (COCP) is 9%, but with perfect use, it drops to 0.3%. However, the risk of unintended pregnancy is even lower with other methods such as the progestogen implant (0.05%), the LNG-IUD (0.2%), and the copper IUD (0.8%) for typical use. The highest risk of unintended pregnancy is associated with the typical use of DMPA, which has a 6% failure rate. It’s important to consider these risks when choosing a contraceptive method that works best for you.

When starting the combined oral contraceptive pill, it is important to inform women that there is a slight increase in the risk of breast and cervical cancer. However, it is also important to note that the pill is protective against ovarian and endometrial cancer.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than one per 100 woman years. It is a convenient option that doesn’t interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to consider. One of the main drawbacks is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections, so additional precautions may be necessary. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side effects such as headache, nausea, and breast tenderness may also be experienced.

Despite some reports of weight gain, a Cochrane review did not find a causal relationship between the combined oral contraceptive pill and weight gain. Overall, the combined oral contraceptive pill can be a safe and effective option for birth control, but it is important to weigh the pros and cons and discuss any concerns with a healthcare provider.

The FSRH has issued UKMEC recommendations for the combined oral contraceptive pill (COCP) due to the heightened risk of cardiovascular disease. According to these guidelines, the COCP is classified as UKMEC 2 for individuals under the age of 35. For those over the age of 35 who smoke less than 15 cigarettes per day, the COCP is classified as UKMEC 3. However, for those over the age of 35 who smoke more than 15 cigarettes per day, the COCP is classified as UKMEC 4. Progestogen-only contraceptives, on the other hand, are not associated with an increased risk of cardiovascular disease and are therefore classified as UKMEC 1, regardless of the patient’s age or cigarette intake.

The choice of contraceptive for women may be affected by comorbidities. The FSRH provides UKMEC recommendations for different conditions. Smoking increases the risk of cardiovascular disease, and the COCP is recommended as UKMEC 2 for women under 35 and UKMEC 3 for those over 35 who smoke less than 15 cigarettes/day, but is UKMEC 4 for those who smoke more. Obesity increases the risk of venous thromboembolism, and the COCP is recommended as UKMEC 2 for women with a BMI of 30-34 kg/m² and UKMEC 3 for those with a BMI of 35 kg/m² or more. The COCP is contraindicated for women with a history of migraine with aura, but is UKMEC 3 for those with migraines without aura and UKMEC 2 for initiation. For women with epilepsy, consistent use of condoms is recommended in addition to other forms of contraception. The choice of contraceptive for women taking anti-epileptic medication depends on the specific medication, with the COCP and POP being UKMEC 3 for most medications, while the implant is UKMEC 2 and the Depo-Provera, IUD, and IUS are UKMEC 1. Lamotrigine has different recommendations, with the COCP being UKMEC 3 and the POP, implant, Depo-Provera, IUD, and IUS being UKMEC 1.

Ovulation induction can lead to ovarian hyperstimulation syndrome (OHSS) as a potential side effect. The symptoms of OHSS often involve gastrointestinal discomfort such as bloating, abdominal pain, nausea, vomiting, and diarrhea. Additionally, patients may experience shortness of breath, fever, peripheral edema, and oliguria.

OHSS can range in severity from mild to life-threatening, and can result in complications such as dehydration, thromboembolism, acute kidney injury (AKI), and pulmonary edema. Severe OHSS typically has a delayed onset compared to milder cases. In the given scenario, the patient received a GnRH agonist injection within the past week, indicating that her symptoms may be less severe.

Understanding Ovulation Induction and Its Categories

Ovulation induction is a common treatment for couples who have difficulty conceiving naturally due to ovulation disorders. The process of ovulation requires a balance of hormones and feedback loops between the hypothalamus, pituitary gland, and ovaries. Anovulation can occur due to alterations in this balance, which can be classified into three categories: hypogonadotropic hypogonadal anovulation, normogonadotropic normoestrogenic anovulation, and hypergonadotropic hypoestrogenic anovulation. The goal of ovulation induction is to induce mono-follicular development and subsequent ovulation, leading to a singleton pregnancy.

There are various forms of ovulation induction, starting with the least invasive and simplest management option first. Exercise and weight loss are typically the first-line treatment for patients with polycystic ovarian syndrome, as ovulation can spontaneously return with even a modest 5% weight loss. Letrozole is now considered the first-line medical therapy for patients with PCOS due to its reduced risk of adverse effects on endometrial and cervical mucous compared to clomiphene citrate. Clomiphene citrate is a selective estrogen receptor modulator that acts primarily at the hypothalamus, blocking the negative feedback effect of estrogens. Gonadotropin therapy tends to be the treatment used mostly for women with hypogonadotropic hypogonadism.

One potential side effect of ovulation induction is ovarian hyperstimulation syndrome (OHSS), which can be life-threatening if not identified and managed promptly. OHSS occurs when ovarian enlargement with multiple cystic spaces form, and an increase in the permeability of capillaries leads to a fluid shift from the intravascular to the extra-vascular space. The severity of OHSS varies, with the risk of severe OHSS occurring in less than 1% of all women undergoing ovarian induction. Management includes fluid and electrolyte replacement, anticoagulation therapy, abdominal ascitic paracentesis, and pregnancy termination to prevent further hormonal imbalances.

For women over 40, it is recommended to consider a COC pill containing less than 30 µg ethinylestradiol as the first-line option due to the potentially lower risks of VTE, cardiovascular disease, and stroke compared to formulations with higher doses of estrogen. COCP can also help reduce menstrual bleeding and pain, which may be beneficial for women in this age group. However, it is important to consider special considerations when prescribing COCP to women over 40.

Levonorgestrel or norethisterone-containing COCP preparations should be considered as the first-line option for women over 40 due to the potentially lower risk of VTE compared to formulations containing other progestogens. The UKMEC criteria for women over 40 is 2, while for women from menarche until 40, it is 1. The faculty of sexual and reproductive health recommends the use of COCP until age 50 if there are no other contraindications. Women aged 50 and over should be advised to use an alternative, safer method for contraception.

Extended or continuous COCP regimens can be offered to women for contraception and to control menstrual or menopausal symptoms. COCP is associated with a reduced risk of ovarian and endometrial cancer that lasts for several decades after cessation. It may also help maintain bone mineral density compared to non-use of hormones in the perimenopause.

Although meta-analyses have found a slightly increased risk of breast cancer among women using COCP, there is no significant risk of breast cancer ten years after cessation. Women who smoke should be advised to stop COCP at 35 as this is the age at which excess risk of mortality associated with smoking becomes clinically significant.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

The UKMEC provides guidance for healthcare providers when selecting appropriate contraceptives based on a patient’s medical history. For women with an undiagnosed breast mass, starting the combined hormonal contraceptive pill is considered UKMEC 3, while continuing its use is classified as UKMEC 2. It is important to note that hormonal contraceptives may impact the prognosis of women with current or past breast cancer, which is classified as UKMEC 4 and UKMEC 3, respectively. Women with benign breast conditions or a family history of breast cancer are classified as UKMEC 1.

The choice of contraceptive for women may be affected by comorbidities. The FSRH provides UKMEC recommendations for different conditions. Smoking increases the risk of cardiovascular disease, and the COCP is recommended as UKMEC 2 for women under 35 and UKMEC 3 for those over 35 who smoke less than 15 cigarettes/day, but is UKMEC 4 for those who smoke more. Obesity increases the risk of venous thromboembolism, and the COCP is recommended as UKMEC 2 for women with a BMI of 30-34 kg/m² and UKMEC 3 for those with a BMI of 35 kg/m² or more. The COCP is contraindicated for women with a history of migraine with aura, but is UKMEC 3 for those with migraines without aura and UKMEC 2 for initiation. For women with epilepsy, consistent use of condoms is recommended in addition to other forms of contraception. The choice of contraceptive for women taking anti-epileptic medication depends on the specific medication, with the COCP and POP being UKMEC 3 for most medications, while the implant is UKMEC 2 and the Depo-Provera, IUD, and IUS are UKMEC 1. Lamotrigine has different recommendations, with the COCP being UKMEC 3 and the POP, implant, Depo-Provera, IUD, and IUS being UKMEC 1.

Breastfeeding Problems and Management

Breastfeeding can come with its own set of challenges, but most of them can be managed with proper care and attention. Some common issues include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These problems can be addressed by seeking advice on positioning, breast massage, and using appropriate creams and suspensions.

Mastitis is a more serious condition that affects around 1 in 10 breastfeeding women. It is important to seek treatment if symptoms persist or worsen, including systemic illness, nipple fissures, or infection. The first-line antibiotic is flucloxacillin, and breastfeeding or expressing should continue during treatment. If left untreated, mastitis can lead to a breast abscess, which requires incision and drainage.

Breast engorgement is another common issue that can cause pain and discomfort. It usually occurs in the first few days after birth and can affect both breasts. Hand expression of milk can help relieve the discomfort of engorgement, and complications can be avoided by addressing the issue promptly.

Raynaud’s disease of the nipple is a less common but still significant problem that can cause pain and blanching of the nipple. Treatment options include minimizing exposure to cold, using heat packs, avoiding caffeine and smoking, and considering oral nifedipine.

Concerns about poor infant weight gain can also arise, prompting consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight until weight gain is satisfactory is also recommended. With proper management and support, most breastfeeding problems can be overcome, allowing for a successful and rewarding breastfeeding experience.

Bartholin’s cysts that are asymptomatic do not need any treatment and can be managed conservatively.

In cases where the cysts are recurrent or causing discomfort, marsupialisation or balloon catheter insertion can be considered as management options. These procedures have been shown to decrease the likelihood of recurrence.

If an abscess is suspected, antibiotics may be necessary. Symptoms of an abscess include pain, swelling, redness, and fever.

Women who are 40 years old or older should be referred for a biopsy to rule out the possibility of carcinoma.

Bartholin’s cyst occurs when the Bartholin duct’s entrance becomes blocked, causing mucous to build up behind the blockage and form a mass. This blockage is usually caused by vulval oedema and is typically sterile. These cysts are often asymptomatic and painless, but if they become large, they may cause discomfort when sitting or superficial dyspareunia. On the other hand, Bartholin’s abscess is extremely painful and can cause erythema and deformity of the affected vulva. Bartholin’s abscess is more common than the cyst, likely due to the asymptomatic nature of the cyst in most cases.

Bartholin’s cysts are usually unilateral and 1-3 cm in diameter, and they should not be palpable in healthy individuals. Limited data suggest that around 3000 in 100,000 asymptomatic women have Bartholin’s cysts, and these cysts account for 2% of all gynaecological appointments. The risk factors for developing Bartholin’s cyst are not well understood, but it is thought to increase in incidence with age up to menopause before decreasing. Having one cyst is a risk factor for developing a second.

Asymptomatic cysts generally do not require intervention, but in older women, some gynaecologists may recommend incision and drainage with biopsy to exclude carcinoma. Symptomatic or disfiguring cysts can be treated with incision and drainage or marsupialisation, which involves creating a new orifice through which glandular secretions can drain. Marsupialisation is more effective at preventing recurrence but is a longer and more invasive procedure. Antibiotics are not necessary for Bartholin’s cyst without evidence of abscess.

References:
1. Berger MB, Betschart C, Khandwala N, et al. Incidental Bartholin gland cysts identified on pelvic magnetic resonance imaging. Obstet Gynecol. 2012 Oct;120(4):798-802.
2. Kaufman RH, Faro S, Brown D. Benign diseases of the vulva and vagina. 5th ed. Philadelphia, PA: Elsevier Mosby; 2005:240-249.
3. Azzan BB. Bartholin’s cyst and abscess: a review of treatment of 53 cases. Br J Clin Pract. 1978 Apr;32(4):101-2.

If a woman is 55 years or older and experiences postmenopausal bleeding (i.e. bleeding occurring more than 12 months after her last menstrual cycle), she should be referred through the suspected cancer pathway within 2 weeks to rule out endometrial cancer. As this woman is over 50 years old and has not had a menstrual cycle for over a year, she has reached menopause and doesn’t require blood tests to confirm it. The recent vaginal bleeding she has experienced is considered postmenopausal bleeding and requires further investigation to eliminate the possibility of endometrial cancer.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Symptoms of endometrial cancer include postmenopausal bleeding, which is usually slight and intermittent at first before becoming heavier, and changes in intermenstrual bleeding for premenopausal women. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness of less than 4 mm. Hysteroscopy with endometrial biopsy is also commonly used for diagnosis. Treatment for localized disease typically involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may require postoperative radiotherapy. Progestogen therapy may be used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

Recognizing Risk Factors for Ovarian Cancer in Primary Care

It can be challenging to diagnose ovarian cancer in primary care, as patients often present with vague abdominal symptoms. However, early detection is crucial for improving outcomes. One way to increase early detection rates is to recognize the risk factors for ovarian cancer. The Macmillan organization has compiled a list of possible risk factors, including family history, age, early menarche, late menopause, HRT use, endometriosis, and ovarian cysts before the age of 30. Protective factors include pregnancy, increased numbers of children, combined oral contraceptive use, and hysterectomy. By asking a few questions about risk factors and family history, primary care providers can better assess the risk of ovarian cancer in their patients. It is important to consider ovarian cancer as a possibility, particularly in women with predominantly gastrointestinal symptoms. By recognizing the risk factors and being alert to the possibility of ovarian cancer, primary care providers can improve early detection rates and ultimately improve patient outcomes.

Trichomoniasis is a sexually transmitted infection caused by a protozoan parasite called Trichomonas vaginalis. It is more common in women than men, and many women with the infection do not experience any symptoms. In order to diagnose trichomoniasis, a sample of vaginal discharge is collected and examined under a microscope for the presence of motile trophozoites. Confirmation of the diagnosis can be done through molecular testing. Treatment typically involves taking oral metronidazole for a specified period of time. Other sexually transmitted infections, such as Chlamydia, gonorrhea, and candidiasis, require different treatments.

Comparison of Bacterial Vaginosis and Trichomonas Vaginalis

Bacterial vaginosis and Trichomonas vaginalis are two common sexually transmitted infections that affect women. Bacterial vaginosis is caused by an overgrowth of bacteria in the vagina, while Trichomonas vaginalis is caused by a protozoan parasite. Both infections can cause vaginal discharge and vulvovaginitis, but Trichomonas vaginalis may also cause urethritis in men.

The vaginal discharge in bacterial vaginosis is typically thin and grayish-white, with a fishy odor. The pH of the vagina is usually higher than 4.5. In contrast, the discharge in Trichomonas vaginalis is offensive, yellow/green, and frothy. The cervix may also appear like a strawberry. The pH of the vagina is also higher than 4.5.

To diagnose bacterial vaginosis, a doctor may perform a pelvic exam and take a sample of the vaginal discharge for testing. The presence of clue cells, which are vaginal cells covered in bacteria, is a hallmark of bacterial vaginosis. On the other hand, Trichomonas vaginalis can be diagnosed by examining a wet mount under a microscope. The motile trophozoites of the parasite can be seen in the sample.

Both bacterial vaginosis and Trichomonas vaginalis can be treated with antibiotics. Metronidazole is the drug of choice for both infections. For bacterial vaginosis, a course of oral metronidazole for 5-7 days is recommended. For Trichomonas vaginalis, a one-off dose of 2g metronidazole may also be used. It is important to complete the full course of antibiotics to ensure that the infection is fully treated.

When switching from a traditional POP to COCP, 7 days of barrier contraception is needed. The safest option is to recommend 7 days of barrier contraception while commencing the combined oral contraceptive to prevent unwanted pregnancy. 10 or 14 days of additional barrier contraception is not required, and 3 days is too short. It is safest to recommend 7 days of additional contraception.

Special Situations for Combined Oral Contraceptive Pill

Concurrent Antibiotic Use:
In the UK, doctors have previously advised that taking antibiotics concurrently with the combined oral contraceptive pill may interfere with the enterohepatic circulation of oestrogen, making the pill ineffective. As a result, extra precautions were advised during antibiotic treatment and for seven days afterwards. However, this approach is not taken in the US or most of mainland Europe. In 2011, the Faculty of Sexual & Reproductive Healthcare updated their guidelines, abandoning the previous approach. The latest edition of the British National Formulary (BNF) has also been updated in line with this guidance. Precautions should still be taken with enzyme-inducing antibiotics such as rifampicin.

Switching Combined Oral Contraceptive Pills:
The BNF and Faculty of Sexual & Reproductive Healthcare (FSRH) appear to give contradictory advice on switching combined oral contraceptive pills. The Clinical Effectiveness Unit of the FSRH has stated in the Combined Oral Contraception guidelines that the pill-free interval doesn’t need to be omitted. However, the BNF advises missing the pill-free interval if the progesterone changes. Given the uncertainty, it is best to follow the BNF.

Implanon and Nexplanon are both subdermal contraceptive implants that slowly release the hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is an updated version of Implanon with a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It doesn’t contain estrogen, making it suitable for women with a history of thromboembolism or migraines. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraception is required for the first 7 days if not inserted on days 1-5 of the menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs may reduce the efficacy of Nexplanon, and women should switch to a different method or use additional contraception until 28 days after stopping the treatment. Contraindications include ischaemic heart disease/stroke, unexplained vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Breast cancer is a UKMEC 4 condition, meaning it represents an unacceptable risk if the contraceptive method is used.

Letrozole and its Side Effects

Letrozole is a medication used to treat postmenopausal women with oestrogen-receptor positive breast cancer. However, it is not recommended for premenopausal women. The British National Formulary (BNF) lists the frequency of side effects as very common, common, uncommon, rare, and very rare. Letrozole’s less common side effects include cough and leucopenia, while vulvovaginal disorders are listed as uncommon. Pulmonary embolism is a rare side effect. On the other hand, osteoporosis and bone fractures are more common side effects, and patients should have their bone mineral density assessed before treatment and at regular intervals. The BNF also cautions that patients may be susceptible to osteoporosis. It is important to be aware of these potential side effects when prescribing Letrozole.

If a woman is not starting her contraceptive method on the first day of her period, the only option that will be effective immediately is an intrauterine device (IUD). This device is a T-shaped plastic device that contains copper and is inserted into the uterus to provide contraception immediately.

Other methods, such as the contraceptive injection, implant, and combined oral contraceptive (COC), as well as the intrauterine system (IUS), require 7 days to become effective if not started on the first day of menstruation. The progesterone-only pill (POP) is also not the best choice as it requires 2 days before becoming effective and must be taken every day. It is important to consider the effectiveness and convenience of each method when choosing a contraceptive.

Implanon and Nexplanon are both subdermal contraceptive implants that slowly release the hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is an updated version of Implanon with a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It doesn’t contain estrogen, making it suitable for women with a history of thromboembolism or migraines. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraception is required for the first 7 days if not inserted on days 1-5 of the menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs may reduce the efficacy of Nexplanon, and women should switch to a different method or use additional contraception until 28 days after stopping the treatment. Contraindications include ischaemic heart disease/stroke, unexplained vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Breast cancer is a UKMEC 4 condition, meaning it represents an unacceptable risk if the contraceptive method is used.

Transdermal HRT is a safer option than oral HRT for women at risk of VTE, according to NICE guidelines. Sharon’s BMI puts her at risk of VTE, so prescribing oral HRT would not be appropriate. Recommending lifestyle changes would not be effective as Sharon has already tried this. Seeking specialist advice is unnecessary as starting transdermal HRT in primary care is safe and reasonable. While antidepressants can be considered for menopausal symptoms, it is not necessary in this case as HRT is a viable option for Sharon.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen, to alleviate menopausal symptoms. However, this treatment can have side-effects such as nausea, breast tenderness, fluid retention, and weight gain.

Moreover, there are potential complications associated with HRT. One of the most significant risks is an increased likelihood of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative (WHI) study found that the relative risk of developing breast cancer was 1.26 after five years of HRT use. The risk of breast cancer is related to the duration of HRT use, and it begins to decline when the treatment is stopped. Additionally, HRT use can increase the risk of endometrial cancer, which can be reduced but not eliminated by adding a progestogen.

Another potential complication of HRT is an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT doesn’t appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any HRT treatment, even transdermal. Finally, HRT use can increase the risk of stroke and ischaemic heart disease if taken more than ten years after menopause.

In conclusion, while HRT can be an effective treatment for menopausal symptoms, it is essential to be aware of the potential adverse effects and complications associated with this treatment. Women should discuss the risks and benefits of HRT with their healthcare provider before starting any treatment.

If a woman has two consecutive inadequate samples during cervical cancer screening, she should be referred for colposcopy. This is because if the cytology results are abnormal and show high-grade dyskaryosis (moderate or severe), colposcopy should be offered within 2 weeks. For those with inadequate, borderline, or low-grade dyskaryosis (mild) results, they should receive an appointment within 6 weeks. It is not possible for the woman to return to routine recall as her samples were inadequate. Repeat hrHPV tests would only be necessary if the woman had positive hrHPV and normal cytology results.

Understanding Cervical Cancer Screening Results

The cervical cancer screening program has evolved significantly in recent years, with the introduction of HPV testing allowing for further risk stratification. The NHS now uses an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

If the hrHPV test is negative, individuals can return to normal recall, unless they fall under the test of cure pathway, untreated CIN1 pathway, or require follow-up for incompletely excised cervical glandular intraepithelial neoplasia (CGIN) / stratified mucin producing intraepithelial lesion (SMILE) or cervical cancer. If the hrHPV test is positive, samples are examined cytologically, and if the cytology is abnormal, individuals will require colposcopy.

If the cytology is normal but the hrHPV test is positive, the test is repeated at 12 months. If the repeat test is still hrHPV positive and cytology is normal, a further repeat test is done 12 months later. If the hrHPV test is negative at 24 months, individuals can return to normal recall, but if it is still positive, they will require colposcopy. If the sample is inadequate, it will need to be repeated within 3 months, and if two consecutive samples are inadequate, colposcopy will be required.

For individuals who have previously had CIN, they should be invited for a test of cure repeat cervical sample in the community 6 months after treatment. The most common treatment for cervical intraepithelial neoplasia is large loop excision of transformation zone (LLETZ), which may be done during the initial colposcopy visit or at a later date depending on the individual clinic. Cryotherapy is an alternative technique.

If you experience ovarian hyperstimulation syndrome, your chances of developing ovarian torsion are higher. This is because the ovary becomes enlarged, which increases the risk of torsion. If you experience sudden pelvic pain and vomiting on one side, it may be a sign of ovarian torsion.

While an ovarian cyst can cause pelvic pain, the sudden onset of pain suggests a cyst accident, such as rupture, haemorrhage, or torsion.

Pelvic inflammatory disease typically causes pelvic pain, fever, and abnormal vaginal bleeding.

Appendicitis usually causes pain in the right iliac fossa.

Understanding Ovarian Torsion

Ovarian torsion is a condition where the ovary twists on its supporting ligaments, leading to a compromised blood supply. This can result in partial or complete torsion of the ovary. When the fallopian tube is also affected, it is referred to as adnexal torsion. The condition is commonly associated with ovarian masses, pregnancy, and ovarian hyperstimulation syndrome. Women of reproductive age are also at risk of developing ovarian torsion.

The most common symptom of ovarian torsion is sudden, severe abdominal pain that is often colicky in nature. Other symptoms include vomiting, distress, and in some cases, fever. Adnexal tenderness may be detected during a vaginal examination. Ultrasound may reveal free fluid or a whirlpool sign. Laparoscopy is usually both diagnostic and therapeutic for ovarian torsion.

Mirena® License for Contraception and Endometrial Hyperplasia Protection

At the moment, question stats are not available, but it is likely that many people will choose 5 years as the answer for Mirena®’s duration of use for contraception. However, it is important to note that while Mirena® is licensed for up to 5 years for contraception and idiopathic menorrhagia, it is only licensed for 4 years for protection against endometrial hyperplasia during oestrogen replacement therapy. This means that individuals using Mirena® for this purpose should have it replaced after 4 years to ensure continued protection. It is crucial to follow the recommended duration of use for Mirena® to ensure its effectiveness and safety.

A labial lump and inguinal lymphadenopathy in an older woman may indicate the presence of vulval carcinoma, as these symptoms are concerning and should not be ignored. Although labial lumps are not uncommon, it is important to be vigilant and seek medical attention if a new lump appears.

Understanding Vulval Carcinoma

Vulval carcinoma is a type of cancer that affects the vulva, which is the external female genitalia. It is a relatively rare condition, with only around 1,200 cases diagnosed in the UK each year. The majority of cases occur in women over the age of 65 years, and the most common type of vulval cancer is squamous cell carcinoma, accounting for around 80% of cases.

There are several risk factors associated with vulval carcinoma, including human papillomavirus (HPV) infection, vulval intraepithelial neoplasia (VIN), immunosuppression, and lichen sclerosus. Symptoms of vulval carcinoma may include a lump or ulcer on the labia majora, inguinal lymphadenopathy, and itching or irritation.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and doesn’t occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this condition.

If a woman experiences both deep dyspareunia and lower abdominal pain, it is probable that she has endometriosis. However, if she is trying to conceive, she cannot use initial treatment options like the combined pill. To confirm the diagnosis, a laparoscopy is the preferred method. A pelvic ultrasound is not the most effective way to diagnose endometriosis and may not show any abnormalities in cases of mild to moderate disease.

Endometriosis is a condition where endometrial tissue grows outside of the uterus, affecting around 10% of women of reproductive age. Symptoms include chronic pelvic pain, painful periods, pain during sex, and subfertility. Diagnosis is made through laparoscopy, and treatment depends on the severity of symptoms. First-line treatments include NSAIDs and hormonal treatments such as the combined oral contraceptive pill or progestogens. If these do not improve symptoms or fertility is a priority, referral to secondary care may be necessary. Treatment options in secondary care include GnRH analogues and surgery, with laparoscopic excision or ablation of endometriosis plus adhesiolysis recommended for women trying to conceive. Ovarian cystectomy may also be necessary for endometriomas.

Cervical Screening in the UK

Cervical screening is recommended for all women in England aged 25-64, and from 20 onwards in Wales and Scotland. This screening is important because certain human papillomavirus (HPV) subtypes underlie the development of almost all cases of cervical cancer. HPV is transmitted during sexual intercourse and intimate sexual contact, and even homosexual women can still pass the virus on to female partners.

Women who have been vaccinated as part of the national HPV programme will be protected against the main two HPV subtypes that cause the majority of cervical cancers, but there are other less common subtypes that can lead to cervical cancer that they are not vaccinated against. Women with a previously abnormal smear require follow up either with further smears or referral for colposcopy/treatment depending on the exact abnormalities detected.

Women who have never been sexually active would be very low risk so following discussion with their GP often may decide not to participate in cervical screening. However, they are eligible to be screened routinely and would be offered screening. The only group above who are not eligible for routine cervical screening are women over the age of 65. Routine screening runs up to the age of 64. However, if a woman has abnormalities that require further follow up smears then this would of course be done beyond the age of 65 if clinically indicated.

In summary, cervical screening is an important part of women’s health in the UK, and all women should consider participating in routine screening to help prevent cervical cancer.

Breast Lumps and Referral to a Breast Clinic

Breast lumps are a common concern among women, and it is important to know when to seek medical attention. If a woman over the age of 30 has a discrete lump that persists after their next period or presents after menopause, referral to a breast clinic should be considered. However, if the lump is of very recent onset and the patient is premenstrual, referral may not be necessary at this stage.

Benign breast lumps tend to be firm or rubbery, often painful, regular or smooth, mobile, and have no nipple or skin signs. On the other hand, malignant lumps are hard, 90% painless, irregular, fixed, and may have skin dimpling, nipple retraction, or bloody discharge.

It is important to note that evening primrose oil is not a treatment for breast lumps, and there is little evidence to suggest it helps with mastalgia. Despite being marketed as a treatment for this condition, it is not a substitute for medical advice and evaluation.

A woman under 30 years old who presents with an unexplained breast lump, with or without pain, may not meet the 2-week-wait referral criteria but can still be referred for further evaluation. The most likely diagnosis is a fibroadenoma, which is a common benign breast lump that often occurs in younger women. These lumps are typically firm, smooth, and highly mobile, and can be described as a breast mouse due to their tendency to move away from the examiner’s hand. While a referral to a breast clinic is necessary, routine referral is appropriate given the low likelihood of cancer. There is no need to arrange mammograms or ultrasounds as these will be done by the breast clinic. Reviewing the patient in one month is unnecessary as the lump has persisted for two months and is not cyclical. Urgent referral to a breast clinic is not necessary given the patient’s age and low likelihood of breast cancer. According to NICE CKS, a 2-week-wait referral is recommended for those over 30 years old with an unexplained breast lump, or over 50 years old with unilateral nipple changes. Consideration of a 2-week-wait referral is also recommended for those over 30 years old with an unexplained lump in the axilla or skin changes suggestive of breast cancer.

In 2015, NICE released guidelines for referring individuals suspected of having breast cancer. If a person is 30 years or older and has an unexplained breast lump with or without pain, they should be referred using a suspected cancer pathway referral for an appointment within two weeks. Similarly, if a person is 50 years or older and experiences discharge, retraction, or other concerning changes in one nipple only, they should also be referred using this pathway. If a person has skin changes that suggest breast cancer or is 30 years or older with an unexplained lump in the axilla, a suspected cancer pathway referral should be considered for an appointment within two weeks. For individuals under 30 years old with an unexplained breast lump with or without pain, a non-urgent referral should be considered.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

The causes of amenorrhoea vary depending on the type. Primary amenorrhoea may be caused by gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, and thyrotoxicosis. Meanwhile, secondary amenorrhoea may be caused by stress, excessive exercise, PCOS, Sheehan’s syndrome, Asherman’s syndrome, and other underlying medical conditions.

To diagnose amenorrhoea, initial investigations may include pregnancy tests, full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels. Management of amenorrhoea involves treating the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause and treat the underlying cause accordingly. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis and other complications.

In conclusion, amenorrhoea is a condition that requires proper diagnosis and management. Understanding the causes and appropriate investigations can help in providing the necessary treatment and care for women experiencing this condition.

The patient has breast engorgement and should be advised to feed the infant with no restrictions on frequency and length of feeds. Analgesia with opioids is not recommended, and support measures such as breast massage and cold gel packs are the mainstay of treatment. Mastitis is a differential diagnosis, but hospital admission is not necessary unless there are signs of sepsis or rapidly progressing infection. Other causes of breast pain or discomfort in breastfeeding women include a full breast, a blocked duct, mastitis, or a breast abscess. Deep breast pain may also be caused by ductal infection, spasm of the ducts, persistent reaction to nerve trauma, or prolactin-induced mastalgia.

Breastfeeding Problems and Management

Breastfeeding can come with its own set of challenges, but most of them can be managed with proper care and attention. Some common issues include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These problems can be addressed by seeking advice on positioning, breast massage, and using appropriate creams and suspensions.

Mastitis is a more serious condition that affects around 1 in 10 breastfeeding women. It is important to seek treatment if symptoms persist or worsen, including systemic illness, nipple fissures, or infection. The first-line antibiotic is flucloxacillin, and breastfeeding or expressing should continue during treatment. If left untreated, mastitis can lead to a breast abscess, which requires incision and drainage.

Breast engorgement is another common issue that can cause pain and discomfort. It usually occurs in the first few days after birth and can affect both breasts. Hand expression of milk can help relieve the discomfort of engorgement, and complications can be avoided by addressing the issue promptly.

Raynaud’s disease of the nipple is a less common but still significant problem that can cause pain and blanching of the nipple. Treatment options include minimizing exposure to cold, using heat packs, avoiding caffeine and smoking, and considering oral nifedipine.

Concerns about poor infant weight gain can also arise, prompting consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight until weight gain is satisfactory is also recommended. With proper management and support, most breastfeeding problems can be overcome, allowing for a successful and rewarding breastfeeding experience.